Clinical trials: Type 2 Diabetes, completed
Type 2 Diabetes, Obese Diabetics
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
This study explores the long-term effects of dapagliflozin and empagliflozin on CYP8B1 gene expression and a range of metabolic, oxidative, and inflammatory biomarkers in obese patients with Type 2 Diabetes Mellitus (T2DM).
- Conditions
- Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
- Trial name
- CYP8B1-SGLT2-T (NCT07120828)
- Testing
- Empagliflozin (oral), Dapagliflozin (DAPA), Metfomin
- Where
- Iraq
- Volunteers
- 260 people
- Sponsor
- Erbil Polytechnic University
Type 2 Diabetes
Evidence-based Text Messages to Target Diet and Physical Activity
This research aims to develop a bank of text messages based on behaviour change techniques targeting specific diet and physical activity behaviours in people with type 2 diabetes
- Trial name
- NCT05641402
- Testing
- Text messages
- Where
- United Kingdom
- Volunteers
- 148 people
- Sponsor
- University of Manchester
Type 2 Diabetes
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes
- Trial name
- NCT00147745
- Testing
- Colesevelam, Insulin glargine (Lantus)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Trial to Incentivise Adherence for Diabetes
Type II diabetes is associated with a host of adverse and costly complications, including heart attacks, strokes, blindness, kidney failure, and severe neuropathy that may result in amputations.
- Trial name
- TRIAD (NCT02224417)
- Testing
- Diabetes Educational Program (DEP), DEP + Process Incentive, DEP + Outcome Incentive
- Where
- 2 sites in Singapore
- Volunteers
- 240 people
- Sponsor
- Duke-NUS Graduate Medical School
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/500 mg in healthy male volunteers.
- Trial name
- NCT02685774
- Testing
- Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg, CKD-395 0.25/500mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
Technology Intensified Diabetes Education Study in African Americans
The purpose of this study is to test the usefulness of an intervention that combines technology with diabetes education and skills training.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent
- Trial name
- TIDES (NCT02088658)
- Testing
- Technology Intensified
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- State University of New York at Buffalo
Type 2 Diabetes Mellitus
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR342434 versus Humalog in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 2 diabetes mellitus (T2DM) also using insulin glargine.
- Trial name
- SORELLA2 (NCT02294474)
- Testing
- SAR342434, Humalog, insulin glargine HOE901
- Where
- 103 sites in United States, Argentina and 10 more
- Volunteers
- 505 people
- Sponsor
- Sanofi
Diabetes
Effect of Nutritional Products in Subjects With Type 2 Diabetes
This is a randomized, double blinded, multi treatment, crossover study intended to compare the glycemic and insulinemic response after consuming liquid nutritional products in people with type 2 diabetes.
- Trial name
- NCT02923960
- Testing
- Standard ONS, Diabetes specific ONS 1, Diabetes specific ONS 2
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This is an observational study, in which data from people in the United States (US) with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FIRST-2 (NCT05703880)
- Testing
- Finerenone (Kerendia, BAY948862)
- Where
- 2 sites in United States
- Volunteers
- 15,948 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
The purposes of this study are: to investigate the extent of cardiovascular complications in a representative cohort (n=135) of adult patients with type 2 diabetes; to examine if modern non-invasive assessment can replace…
- Trial name
- NCT00133718
- Testing
- Combined lifestyle intervention and optimisation of pharmacological treatment
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Asker & Baerum Hospital
Diabetes Mellitus, Type 2
Short Message Service for Type 2 Diabetes
Diabetes is a chronic disease where type 1 diabetes (T1D) is due to autoimmune ẞ-cell destruction, usually leading to absolute insulin deficiency, type 2 diabetes (T2D) is due to a progressive loss of ẞ-cell insulin secretion…
- Trial name
- SMS4T2D (NCT04236206)
- Testing
- Mobile Phone Short Message Service
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Supaglutide in Healthy Participants
This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese healthy subjects.
- Trial name
- NCT03745885
- Testing
- Supaglutide injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Diabetic Nephropathy
Nephropathy In Type 2 Diabetes and Cardio-renal Events
The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases: Phase 1(observational study, completed in September 2005): after the identification of a type-2 diabetic population with typical Diabetic…
- Trial name
- NID-2 (NCT00535925)
- Testing
- SoC therapy, irbesartan, ramipril
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- University of Campania Luigi Vanvitelli
Type 2 Diabetes Mellitus
The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04217291
- Testing
- SY-004
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Diabetes, Heart Failure
Multipolar CRT-d and Diabetes
Background: Type 2 Diabetes Mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart (HF) patients treated by Cardiac Resynchronization Therapy with a defibrillator (CRT-d).
- Conditions
- Diabetes, Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT03095196
- Testing
- Multipolar CRT-d, plus conventional drug therapy for HF., Bipolar CRT-d, plus conventional drug therapy for HF., HF drugs
- Volunteers
- 190 people
- Sponsor
- Celestino Sardu
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00671008
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- Bosnia and Herzegovina
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis)…
- Trial name
- NCT01068717
- Testing
- Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Effects of Microfluidic Noodle on Blood Glucose Levels of Healthy Volunteers.
In this study, microfluidics was applied in the creation of low-GI food gel made from non-traditional ingredients like alginate and soy protein isolate.
- Trial name
- NCT03989908
- Testing
- Microfludic noodle, Control noodle
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
Primary Objective: To assess in healthy adult male subjects: The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
- Trial name
- NCT02411825
- Testing
- SAR425899, metformin
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 2 Diabetes
LIraglutide and Beta-cell RepAir (LIBRA) Study
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily…
- Trial name
- LIBRA (NCT01270789)
- Testing
- Liraglutide
- Where
- Canada
- Volunteers
- 63 people
- Sponsor
- Mount Sinai Hospital, Canada
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.